Chimeric antigen receptor (CAR) T cell immunotherapy involves the genetic modification of the patient’s own T cells so that they specifically recognize and destroy tumour cells. Considerable clinical success has been achieved using this technique in patients with lymphoid malignancies, but clinical studies that investigated treating solid tumours using this emerging technology have been disappointing. A number of developments might be able to increase the efficacy of CAR T cell therapy for treatment of prostate cancer, including improved trafficking to the tumour, techniques to overcome the immunosuppressive tumour microenvironment, as well as methods to enhance CAR T cell persistence, specificity and safety. Furthermore, CAR T cell therapy has the potential to be combined with other treatment modalities, such as androgen deprivation therapy, radiotherapy or chemotherapy, and could be applied as focal CAR T cell therapy for prostate cancer.

嵌合抗原受体 (CAR) T 细胞免疫疗法涉及对患者自身的 T 细胞进行基因改造，使其能够特异性识别和破坏肿瘤细胞。使用这种技术在淋巴恶性肿瘤患者中取得了相当大的临床成功，但研究使用这种新兴技术治疗实体瘤的临床研究令人失望。许多发展可能能够提高 CAR T 细胞疗法治疗前列腺癌的疗效，包括改善对肿瘤的运输、克服免疫抑制性肿瘤微环境的技术，以及增强 CAR T 细胞持久性、特异性和稳定性的方法。安全。此外，CAR T 细胞疗法有可能与其他治疗方式相结合，例如雄激素剥夺疗法，